Wilmer Cutler Pickering Hale and Dorr LLP represented Thermo Fisher Scientific Inc. in its public offering.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced hat it has priced an offering of €1.2 billion aggregate principal amount of €600 million aggregate principal amount of 1.750% Senior Notes due 2027, priced at 99.190% of principal, and €600 million aggregate principal amount of 2.375% Senior Notes due 2032, priced at 98.940% of principal.
The net proceeds of the offering will be used, with the proceeds of the US offering described above, to pay a portion of the purchase price of the previously announced acquisition of QIAGEN N.V. and for general corporate purposes.
The offering priced on March 30, 2020 and closed on April 2, 2020.
Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals. The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.
The WilmerHale team consisted of Erika Robinson (Picture), Justin Ochs, Knute Salhus, Julie Hogan Rodgers, Alan Wilson, Jenny Moore and Alex Bernstein.
Law Firms: WilmerHale;
Clients: Thermo Fisher Scientific;